Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Operations (2020 - 2025)

Apellis Pharmaceuticals has reported Cash from Operations over the past 6 years, most recently at 14176000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 14176000.0 for Q4 2025, down 173.22% from a year ago — trailing twelve months through Dec 2025 was 45327000.0 (up 151.59% YoY), and the annual figure for FY2025 was 45327000.0, up 151.59%.
  • Cash from Operations for Q4 2025 was 14176000.0 at Apellis Pharmaceuticals, down from 108468000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for APLS hit a ceiling of 108468000.0 in Q3 2025 and a floor of 177620000.0 in Q1 2023.
  • Median Cash from Operations over the past 5 years was 112029500.0 (2021), compared with a mean of 85707250.0.
  • Biggest five-year swings in Cash from Operations: crashed 179.24% in 2021 and later soared 218.13% in 2025.
  • Apellis Pharmaceuticals' Cash from Operations stood at 112499000.0 in 2021, then fell by 25.11% to 140744000.0 in 2022, then surged by 30.46% to 97875000.0 in 2023, then soared by 119.78% to 19360000.0 in 2024, then plummeted by 173.22% to 14176000.0 in 2025.
  • The last three reported values for Cash from Operations were 14176000.0 (Q4 2025), 108468000.0 (Q3 2025), and 4445000.0 (Q2 2025) per Business Quant data.